cagrilintide semaglutide combination phase 3 2024 Three new REIMAGINE studies provide some of the strongest evidence yet for CagriSema® (cagrilintide + semaglutide) in type 2 diabetes. 🔹 REIMAGINE 1 Studied people with early type 2 diabetes Cagrilintide lowers bodyweight through brain
Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3 eBioMedicine cagrilintide semaglutide combination cagrisema phase 3 results 2024 2025 NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study Amylin Commands Weight Loss Attention as Industry Anticipates Novo's Phase III CagriSema Readout BioSpace Novo Nordisk's CagriSema 2.4 mg 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
Pay in 4 interest-free payments of $6.03 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24


